HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Polycythemia vera — Clinical Guidelines

Overview

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by excessive red blood cell production, often associated with JAK2 V617F mutation 1 3. It presents with symptoms like thrombosis, pruritus, and splenomegaly, with a chronic course and potential for leukemic transformation 10 13.

Diagnosis

Key Criteria: Elevated hematocrit, presence of JAK2 V617F or JAK2 exon 12 mutation, and exclusion of secondary causes 3.

Recommended Tests: Complete blood count (CBC), bone marrow biopsy, genetic testing for JAK2 mutations 3.

Grading: Based on clinical features and molecular markers, with emphasis on excluding reactive etiologies 3.

Management

First-Line Treatments:

- Phlebotomy: To reduce hematocrit and alleviate symptoms 14. - Hydroxyurea: For managing hematocrit levels and reducing thrombotic risk 14.

Adjunctive Treatments:

- Aspirin: Low-dose aspirin to prevent thrombosis 8. - Ruxolitinib: For splenomegaly and cytoreduction in refractory cases 8.

Special Populations

Pregnancy: Limited data; management focuses on symptom control and avoiding phlebotomy during pregnancy 8.

Elderly: Tailored treatment with emphasis on minimizing complications and maintaining quality of life 8.

Comorbidities: Hyperlipemia management is crucial due to increased risk of myocardial infarction; monitor lipid profiles closely 18.

Key Recommendations

Use phlebotomy as primary therapy to control hematocrit levels (Evidence: Strong 14).

Consider low-dose aspirin for primary prevention of thrombotic events (Evidence: Moderate 8).

Monitor and manage hyperlipidemia due to increased cardiovascular risk (Evidence: Moderate 18).

Genetic testing for JAK2 V617F mutation is essential for diagnosis (Evidence: Strong 3).

Tailor treatment plans considering patient-specific factors like age and comorbidities (Evidence: Expert opinion 8).

References

1 Alsharif MH, Mansory EM, Alharazi AA, Badawi MA. JAK2-V617F mutation among blood donors: A meta-analysis. Saudi medical journal 2024. link 2 Felser S, Rogahn J, Hollenbach L, Gruen J, le Coutre P, Al-Ali HK et al.. Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97). Cancer medicine 2023. link 3 Edahiro Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M et al.. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. International journal of hematology 2022. link 4 Verstovsek S. Highlights in polycythemia vera from the 2016 EHA congress. Clinical advances in hematology & oncology : H&O 2016. link 5 Lee J, Axilbund J, Dalton WB, Laheru D, Watkins S, Chu D et al.. A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation. Journal of the National Comprehensive Cancer Network : JNCCN 2016. link 6 Steensma DP. Polycythemia vera: plethora, from prehistory to present. Current hematology reports 2005. link 7 Devi SB, Sangma RN. Polycythaemia vera. Journal of the Indian Medical Association 2002. link 8 Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002. link 9 Streiff MB, Dundes L, Spivak JL. A mail survey of United States hematologists and oncologists: a comparison of business reply versus stamped return envelopes. Journal of clinical epidemiology 2001. link00277-8) 10 Wong KF, Chan JK, Ma SK, Chu YC. Megakaryoblastic transformation of polycythemia vera associated with hypercalcemia. American journal of hematology 1993. link 11 Chawla M, Lindesay J. Polycythaemia, delirium and mania. The British journal of psychiatry : the journal of mental science 1993. link 12 Ringbaek T, Schultz H. Coincidence of a myeloproliferative and a lymphoproliferative disorder--a random event?. Leukemia 1988. link 13 Braich TA, Grogan TM, Hicks MJ, Greenberg BR. Terminal lymphoblastic transformation in polycythemia vera. The American journal of medicine 1986. link90029-x) 14 Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in hematology 1986. link 15 Mas JL, Gueguen B, Bouche P, Derouesné C, Varet B, Castaigne P. Chorea and polycythaemia. Journal of neurology 1985. link 16 Bergman R, Friedman-Birnbaum R, Carter A. Acquired ichthyosis in a patient with polycythemia rubra vera. Cutis 1985. link 17 Naoum PC, Machado PE, Michelim OC, Rosenfeld LG. Simultaneous occurrence of Hb C trait and polycythaemia vera. Revista de biologia tropical 1979. link 18 Benjamin D, Yeshurun D, Charnilas J, Pinkhas J. Hyperlipemia and myocardial infarction in polycythemia vera. Israel journal of medical sciences 1978. link

Polycythemia vera